p14ARF protein expression is a predictor of both relapse and survival in squamous cell carcinoma of the anterior tongue

Clinical Cancer Research

Volumn 11, Issue 11, 2005, Pages 4107-4116

  Kwong, Rhonda A ^a   Kalish, Larry H ^a   Nguyen, Tuan V ^a   Kench, James G ^a,c   Bova, Ronaldo J ^b   Cole, Ian E ^b   Musgrove, Elizabeth A ^a   Sutherland, Robert L ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; PROTEIN P14ARF; PROTEIN P16INK4A; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1; TUMOR SUPPRESSOR PROTEIN; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DNA BINDING PROTEIN; E2F1 PROTEIN, HUMAN; KI 67 ANTIGEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F;

ARTICLE; AUSTRALIA; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; CHROMOSOME 9P; COHORT ANALYSIS; GENE LOCUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NONBIOLOGICAL MODEL; NUCLEOLUS; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TONGUE CARCINOMA; BIOSYNTHESIS; METABOLISM; PATHOLOGY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; SURVIVAL; TONGUE TUMOR; TUMOR RECURRENCE;

CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; COHORT STUDIES; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETINOBLASTOMA PROTEIN; SURVIVAL ANALYSIS; TONGUE NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 20344398913     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2036     Document Type: Article

References (49)

1. Registry NCC. Cancer in NSW incidence and mortality 2001 report. Sydney (Australia): NSW Cancer Council; 2003. p. 288.
2. Kleihues P, Stewart BW. World cancer report. Geneva (Switzerland): WHO and IARC; 2003.
3. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2:103-12.
4. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
5. Piboonniyom SO, Timmermann S, Hinds P, Munger K. Aberrations in the MTS1 tumor suppressor locus in oral squamous cell carcinoma lines preferentially affect the INK4A gene and result in increased cdk6 activity. Oral Oncol 2002;38:179-86.
6. Bova RJ, Quinn DI, Nankervis JS, et al. Cyclin D1 and P16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res 1999;5:2810-9.
7. 1-S cell cycle control in head and neck cancer: a review. Head Neck 2002;24:694-704.
8. van Houten VM, Tabor MP, van den Brekel MW, et al. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. J Pathol 2002;198:476-86.
9. Weber A, Bellmann U, Bootz F, Wittekind C, Tannapfel A. Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck. Int J Cancer 2002;99:22-8.
10. Bates S, Hickman ES, Vousden KH. Reversal of p53-induced cell-cycle arrest. Mol Carcinog 1999;24:7-14.
11. Bates S, Vousden KH. Mechanisms of p53-mediated apoptosis. Cell Mol Life Sci 1999;55:28-37.
12. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A 1998;95:8292-7.
13. Tao W, Levine AJ. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci U S A 1999;96:6937-41.
14. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1999;1:20-6.
15. Pomerantz J, Schreiber-Agus N, Liegeois NJ, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-23.
16. Llanos S, Clark PA, Rowe J, Peters G. Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nat Cell Biol 2001;3:445-52.
17. Korgaonkar C, Zhao L, Modestou M, Quelle DE. ARF function does not require p53 stabilization or Mdm2 relocalization. Mol Cell Biol 2002;22:196-206.
18. Yarbrough WG, Bessho M, Zanation A, Bisi JE, Xiong Y. Human tumor suppressor ARF impedes S-phase progression independent of p53. Cancer Res 2002;62:1171-7.
19. Bates S, Phillips AC, Clark PA, et al. p14ARF links the tumour suppressors RB and p53. Nature 1998;395:124-5.
20. Khleif SN, DeGregori J, Yee CL, et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci U S A 1996;93:4350-4.
21. Shintani S, Nakahara Y, Mihara M, Ueyama Y, Matsumura T. Inactivation of the p14(ARF), p15(INK4B) and p16(INK4A) genes is a frequent event in human oral squamous cell carcinomas. Oral Oncol 2001;37:498-504.
22. Weber A, Bellmann U, Bootz F, Wittekind C, Tannapfel A. INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck. Virchows Arch 2002;441:133-42.
23. Reed AL, Califano J, Cairns P, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56:3630-3.
24. Palmero I, Murga M, Zubiaga A, Serrano M. Activation of ARF by oncogenic stress in mouse fibroblasts is independent of E2F1 and E2F2. Oncogene 2002;21:2939-47.
25. Parisi T, Pollice A, Di Cristofano A, Calabro V, La Mantia G. Transcriptional regulation of the human tumor suppressor p14(ARF) by E2F1, E2F2, E2F3, and Sp1-like factors. Biochem Biophys Res Commun 2002;291:1138-45.
26. Kwong RA, Nguyen TV, Bova RJ, et al. Overexpression of E2F-1 is associated with increased disease-free survival in squamous cell carcinoma of the anterior tongue. Clin Cancer Res 2003;9:3705-11.
27. Horvath L, Henshall S. The application of tissue microarrays to cancer research. Pathology 2001;33:125-9.
28. Sutherland RL, Watts CKW, Lee CS, Musgrave EA. Human cell culture. Vol. 2. London (United Kingdom): Kluwer Academic Publishers: 1999. p. 79-106.
29. SAS Institute Inc. SAS technical report P-229, SAS/STAT software: Changes and enhancements. Release 6.07 ed. Gary (NC): SAS Institute, Inc.; 1992. p 443-80.
30. Lindstrom MS, Klangby U, Inoue R, et al. Immunolocalization of human p14(ARF) to the granular component of the interphase nucleolus. Exp Cell Res 2000;256:400-10.
31. DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci U S A 1997;94:7245-50.
32. Stott FJ, Bates S, James MC, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998;17:5001-14.
33. Spiessl B, Beahrs OH, Hermanek P, et al. TNM atlas illustrated guide to the TNM/pTNM classification of malignant tumours. 3rd ed. Berlin (Germany): Springer-Verlag; 1992.
34. Mamelle G, Pampurik J, Luboinski B, Lancar R, Lusinchi A, Bosq J. Lymph node prognostic factors in head and neck squamous cell carcinomas. Am J Surg 1994;168:494-8.
35. Salesiotis AN, Cullen KJ. Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: evolution of a model beyond TNM staging. Curr Opin Oncol 2000;12:229-39.
36. Itahana K, Bhat KP, Jin A, et al. Tumor suppressor ARF degrades B23, a nucleolar protein Involved in ribosome biogenesis and cell proliferation. Mol Cell 2003;12:1151-64.
37. Sugimoto M, Kuo ML, Roussel MF, Sherr CJ. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol Cell 2003;11:415-24.
38. David-Pfeuty T, Nouvian-Dooghe Y. Human p14(Arf): an exquisite sensor of morphological changes and of short-lived perturbations in cell cycle and in nucleolar function. Oncogene 2002;21:6779-90.
39. Lin AW, Löwe SW. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc Natl Acad Sci U S A 2001;98:5025-30.
40. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2:731-7.
41. Kamijo T, Zindy F, Roussel MF, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997;91:649-59.
42. Voorhoeve PM, Agami R. The tumor-suppressive functions of the human INK4A locus. Cancer Cell 2003;4:311-9.
43. Hollstein M, Rice K, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994;22:3551-5.
44. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998;1378:F115-77.
45. Xu L, Chen YT, Huvos AG, et al. Overexpression of p53 protein in squamous cell carcinomas of head and neck without apparent gene mutations. Diagn Mol Pathol 1994;3:83-92.
46. Palmero I, Pantoja C, Serrano M. p19ARF links the tumour suppressor p53 to Ras. Nature 1998;395:125-6.
47. 1 cyclin-dependent kinase activation by interacting with MDM2 and activating p53 in mouse fibroblasts. Oncogene 1999;18:2718-27.
48. Weber JD, Jeffers JR, Rehg JE, et al. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev 2000;14:2358-65.
49. Modestou M, Puig-Antich V, Korgaonkar C, Eapen A, Quelle DE. The alternative reading frame tumor suppressor inhibits growth through p21-dependent and p21-independent pathways. Cancer Res 2001;61:3145-50.